Premium
Studies on the profile of desmethylimipramine as a gastric antisecretory agent
Author(s) -
Pendleton Robert G.,
Miller Darlene A.
Publication year - 1982
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430020412
Subject(s) - atropine , stomach , gastric emptying , medicine , gastric acid , parasympatholytic , desipramine , saliva , gastroenterology , atropine sulfate , endocrinology , chemistry , pharmacology , muscarinic acetylcholine receptor , antidepressant , receptor , hippocampus
Desmethylimipramine (DMI) and atropine were compared in a variety of organ system tests in rats involving parasympathetic function in order to evaluate the specificity of these compounds as gastric antisecretory agents. DMI was similar to atropine in its effects on the stomach; each markedly inhibited gastric acid secretion and stomach emptying and protected against restraint‐induced gastric ulceration. However, unlike atropine, DMI did not substantially increase pupil size, reduce fecal pellet output, cause urinary retention, or increase heart rate. From these data, it is possible that at least certain antidepressant type drugs could be developed for the treatment of peptic ulcer disease.